C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
about
The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in humanPaths reunited: Initiation of the classical and lectin pathways of complement activationTherapeutic regulation of complement in patients with renal disease - where is the promise?Hereditary angioedema: New therapeutic options for a potentially deadly disorder.Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseasesCleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1Expression of the SERPING1 gene is not regulated by promoter hypermethylation in peripheral blood mononuclear cells from patients with hereditary angioedema due to C1-inhibitor deficiency.Pediatric hereditary angioedema due to C1-inhibitor deficiency.Management of upper airway edema caused by hereditary angioedema.The complement systemPotential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat modelDiagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective.Urticaria and angioedema.Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse eventsHereditary angioedema: what the gastroenterologist needs to know.Hereditary angioedema nationwide study in Slovenia reveals four novel mutations in SERPING1 geneEnzymatic assays for the diagnosis of bradykinin-dependent angioedema.Complement system in dermatological diseases - fire under the skinA nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in ItalyKininogen Cleavage Assay: Diagnostic Assistance for Kinin-Mediated Angioedema Conditions.Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.Soluble IgM links apoptosis to complement activation in early alcoholic liver disease in mice.Hereditary angioedema: epidemiology, management, and role of icatibantHereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe.Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency.Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.Therapeutic approaches in hereditary angioedema.Kinin system activation in vasculitis.New therapeutics in C1INH deficiency: a review of recent studies and advances.Disease-causing mutations in genes of the complement system.New topics in bradykinin research.The dermatology view of hereditary angio-oedema: practical diagnostic and management considerations.Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic.Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.Anaesthesia Management of a Patient with Hereditary Angioedema with Prophylactic Administration of C1 Esterase Inhibitor: Case report and literature review.Overview of complement activation and regulationRegulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
P2860
Q21136173-4E4377FA-B07F-44E5-B090-BA500A6E32B8Q24646047-895ACB8C-F789-458B-AA07-47890501700CQ26851705-A21D9830-9A66-45F3-82F7-FEEFA40F7B52Q33578268-566C4785-284E-4148-A49B-634D8F022460Q33667582-9512201A-C3D3-465C-8489-24D3CE665145Q33916226-15F165E2-A6D4-4605-8452-552164CE71E2Q33969976-83CC5D63-CBDC-421B-BB1C-E35750851A84Q34060664-FD22A60C-53CE-4670-8626-3529A9574C72Q34060670-1247418A-8640-4B58-961F-D9F889258917Q34137841-B0B22BB1-D63E-4757-B5A1-8FAAD150E960Q34142474-684F5DDD-F2E6-4A24-B3DC-7444E8101FD0Q34213728-89F1C50C-6A85-4C5B-BDF8-0F60490A6C96Q34215915-781C5CDC-0E3D-4051-BD65-D4C3894A819DQ34238816-1F647284-E7C7-4795-9879-A473E005454AQ34564088-A2BA5CF6-7A3B-4DEC-A8B4-483AC6E346F0Q34599332-E1C8660D-026A-402E-945A-2C88A22C2480Q34934680-1ADB3FD8-76D1-4E82-A178-60E6C20AA2A2Q35026107-410A9D81-13CF-4045-98E3-2A35B147A87AQ35099643-291FE6C2-5792-4DBA-8ED2-4F363E8134D9Q36148583-06AE3625-8BCE-4149-B22D-E2203A9DF08AQ36326043-1B646DA2-AD06-4BF6-B255-D85C0091283BQ36788663-0DA43119-26B2-4F28-BF0A-1C1926CA6D9CQ36825274-CA92FCAD-70CA-4EB1-9D25-72D6D7BA41D0Q37114784-BB76413B-12FE-4B8C-A112-4557B5C3A786Q37410712-F4591792-6FA5-4995-B6E2-CBDAB283EA19Q37531616-800664C2-0633-4410-A399-07C006256A81Q37729036-D1CB2BC1-D449-44CA-B70D-9FC0FC8C895EQ37833531-58234ED1-9632-45EE-8B48-622F97C939D9Q37852784-46BAEB01-0EEC-42A6-A0FB-734BEB62F86EQ37878994-1AF06FDF-FDE6-49ED-B1A6-F4355804E3C2Q37888153-445D4AB7-29C1-4A0C-9AF9-822851CF101EQ37920922-CDEBF7D1-F6BD-4934-BC63-3F00CCB0E31CQ38008439-E23915D1-BE5F-4C30-8EB9-41AE9CC2C6F7Q38042696-0A2661CF-16EF-47A3-B51A-52AFEB1FA2A3Q38058560-2C232820-B849-4347-BEEE-1FBAD45A7C74Q38103288-28D6A969-91FB-4DDF-978E-8593BAE00576Q38132170-E24E61AD-C606-4E86-AC34-614601002C73Q38155650-1876746D-29DC-4769-9FFA-39DB2777895AQ38291696-3541B643-C754-4B36-B712-DF4CE7583101Q38597515-00F048B4-B4D7-48F1-AFA5-3B99FE1C37B5
P2860
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@en
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@nl
type
label
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@en
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@nl
prefLabel
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@en
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@nl
P50
P1476
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
@en
P2093
Andrea Zanichelli
Fabrizio Foieni
P356
10.1016/J.MOLMED.2008.12.001
P577
2009-01-21T00:00:00Z